cyrilzakka/clinical-trials huggingface dataset:
Effects of Electronic Cigarette Settings and Liquid Concentrations in Cigarette Smokers and Electronic Cigarette Users

The purpose of this research study is to find out how different types of electronic cigarettes (ECIG) settings, combined with e-liquids of differing nicotine concentrations, affect blood nicotine levels, use behavior (how users puff), and how users feel.


Eligibility Criteria:
Inclusion Criteria--participants must be:

* healthy (determined by self-report)
* between the ages of 18-55
* willing to provide informed consent
* able to attend the lab and abstain from tobacco/nicotine as required and must agree to use designated products according to study protocol

Exclusion Criteria:

* Women if they are breast-feeding or test positive for pregnancy (by urinalysis) at screening.
* Individuals who weigh less than 110 pounds

Some study details about the eligibility criteria are purposely omitted at this time to preserve scientific integrity. Full details will be posted at the conclusion of the study.
Effect of Intranasal Insulin on POCD and POD

Decline in cognitive function after surgery occurs most commonly in older patients and patients undergoing major surgeries, such as heart surgery. Postoperative Cognitive Dysfunction (POCD) may last a prolonged period of time while Postoperative Delirium (POD) is a more acute disturbance in attention, awareness and cognition. The cause of POCD and POD are not fully understood, however some of the pathophysiology of POCD is similar to that of Alzheimer's disease (AD).

Insulin given intravenously during heart surgery has been shown to preserve short and long-term memory function after the operation. Clinical trials further demonstrated that insulin given via the nose (intranasal) improves memory performance of patients with AD or cognitive impairment suggests that intranasal insulin also could be a therapeutic option for POCD and POD.

This study is designed to examine the effect intranasal insulin on POCD and POD. The goal is to investigate whether administration of intranasal insulin during and after heart surgery improves cognitive function postoperatively.


Eligibility Criteria:
Inclusion Criteria:

•elective open heart surgery requiring cardiopulmonary bypass

Exclusion Criteria:

* inability to provide informed consent
* allergy to insulin
* pregnancy
* mother tongue other than English or French
* visual or hearing impairment interfering with the ability to complete cognitive tests.
Airtime Incentive Amounts to Improve Interactive Voice Response Surveys in Bangladesh and Uganda

This study evaluates the effect of two different airtime incentive amounts on interactive voice response (IVR) survey cooperation, response, refusal, and contact rates, as compared to control group, in Bangladesh and Uganda.

Using random digit dialing sampling techniques, the investigators randomized random digit dialed (RDD) participants to one of three airtime incentive amounts contingent on them completing the noncommunicable disease risk factor survey. This mobile phone survey was sent as an interactive voice response (IVR). In IVR surveys, participants use their touch tone key pad to answer pre-recorded questions. (i.e. If you are male, press 1; If you are female, press 2). This study was conducted in both Bangladesh and Uganda

Eligibility Criteria:
Inclusion Criteria:

* Access to a mobile phone
* Greater or equal to 18 years of age
* In Bangladesh, conversant in either English or Bangla language. In Uganda, conversant in either Luo, Luganda, Runyakitara, or English Languages

Exclusion Criteria:

* Less than 18 years of age
Hallux Valgus Conservative Treatment

Studying the effect of kinesiotape on hallux valgus angle and pain in hallux valgus patients.

30 patients (male and female) suffering from bilateral Halux valgus. Divided randomly into 2 groups

1. st group receive kinesiotape bilaterally for correction : Hallux valgus angle (HVA) was measured using Xray and pain was measured using VAS before applying tape and after 8 weeks of tape application.
2. nd group receive placebo tape bilaterally and had the same measurements.

2 groups were on a group of exercises

Eligibility Criteria:
Inclusion Criteria:

* mobile hallux valgus

Exclusion Criteria:

* using orthotics
* knee malalignment
Lung Ultrasound in Pleuritic Chest Pain

Chest pain is an alarming symptom and one of the most frequent causes of access to the Emergency Departement. Although chest X-ray remains an essential step in the diagnostic process, several studies showed numerous limitations of radiography which frequently is inconclusive. Ultrasonography is a non-radiating imaging technique. Albeit a wide use of ultrasound, the utilization of ultrasound in the study of the lung has only recently been introduced in the clinical practice. Several studies proved that lung ultrasound is useful in the diagnosis of lung consolidation in community acquired pneumonia. Nowadays, ultrasound is not routinely used in the presence of chest pain. Our hypothesis based on clinical experience is that, in patients with pleuritic chest pain, lung ultrasound is very sensitive in detecting pneumonia and other lung diseases (such as pneumothorax) thus performing better than radiography. The primary aim of this study is to verify, in patients affected by pleuritic chest pain, the accuracy of lung ultrasound compared to chest-X-ray. The secondary aim is to evaluate the accuracy of lung ultrasound consolidations in distinguishing lung consolidation in pneumonia, atelectasis, pulmonary infarction, or tumors.


Eligibility Criteria:
Inclusion Criteria:

* patient aged 18 years and older
* patient affected by thoracic pleuritic pain

Exclusion Criteria:

* patient affected by a chronic condition causing thoracic pain
* patient affected by acute cardiovascular diseases (e.g. acute coronary syndrome)
Characteristics Predictive of Pessary Success

Pessaries are mechanical support devices worn vaginally to treat the symptoms of pelvic organ prolapse, such as vaginal pressure or a vaginal bulge. Pessaries are one of the options along with surgery and expectant management for pelvic organ prolapse. As the aging population grows, more patients will need treatment for pelvic organ prolapse. Various studies have been conducted previously to identify patient parameters predictive of successful pessary fitting and continued use. Our study is a retrospective chart review to identify patient characteristics predictive of successful pessary fitting and use, specifically focusing on the parameters of POPQ, pelvic organ prolapse quantification exam, and the ratio of the genital hiatus, which is the length of the vaginal opening, and total vaginal length.


Eligibility Criteria:
Inclusion Criteria:

* undergone a pessary fitting by physicians in the division of Urogynecology between the years of 2000 to 20008.

Exclusion Criteria:

* Patients will be excluded only if their chart does not contain the clinical data under review.
Evaluation of the Efficacy and the Safety of a Stereotaxic Prostatic Radiotherapy Delivered With Linac MRI, in Patients With Prostate Adenocarcinoma

Stereotaxic prostatic radiotherapy on Linac MRI, with monitoring of movements of the pelvic organs per fraction on the prostate in real time, in 4 sessions, with integrated boost on the index tumor (if it is visible on the diagnostic MRI), could reduce the digestive, urinary and sexual toxicities accumulated at 5 years and guarantee excellent local tumor control, for patients with localized prostate cancer, with a favorable prognosis, intermediate or very local high risk, according to the D'Amico classification.

The benefits that patients participating in this research could obtain are:

* Better disease control efficiency
* A reduction in the duration of treatment to 4 radiotherapy sessions (2 weeks maximum) instead of 40 sessions (8 weeks) for usual treatment.
* Avoid the risks associated with the implantation of prostate markers necessary for stereotaxic radiotherapy on a standard accelerator (anesthetic risks, infectious risks, hemorrhagic risks, pain risks)
* Better quality of life


Eligibility Criteria:
Inclusion Criteria:

1. prostate adenocarcinoma
2. WHO performance index ≤ 1
3. Patient presenting one of the following cases:

   * Low risk: ≤ T2a and Gleason 6 (3 + 3) and PSA \<10 ng / ml
   * Intermediate risk: T2b-T2c or Gleason 7 or PSA \<15 ng / ml
   * High localized risk: T3a and Gleason ≤7 and PSA \<15 ng / ml
4. Disease presenting a risk of lymph node involvement \<15%
5. Absence of pelvic or lumbar aortic lymphadenopathy
6. Absence of bone or visceral metastasis
7. IPSS score \<15 or ≤ 7
8. Prostate volume estimated by MRI or ultrasound \< 90cc
9. If hormonotherapy, hormone therapy must not have started for more than 60 days before inclusion.
10. Absence of prior pelvic radiotherapy
11. No surgical treatment for prostate cancer

Exclusion Criteria:

1. Prostate cancer of histology other than adenocarcinoma
2. Contraindication to MRI including, but not limited to, patients with a pacemaker or defibrillator
3. Patient diagnosed N1 during imaging workup or pN1
4. Serum PSA level ≥ 15 ng / ml
5. IPSS score ≥ 15 or IPSS score\> 7 if alpha blocking urological treatment in progress
6. Prostate volume estimated on MRI or ultrasound\> 90 cc
7. Involvement of seminal vesicles on MRI
8. History of cancer in the 5 years preceding entry into the trial
9. History of transurethral resection of the prostate less than 6 months compared to the expected date of start of radiotherapy
10. rectal surgery
11. pelvic irradiation
12. Patient treated with antineoplastic or medication which may include Methotrexate
13. Hormone therapy started for more than 60 days at the time of inclusion
14. Severe uncontrolled hypertension
15. Patient followed or treated for severe or unstable angina, or having presented a myocardial infarction in the 6 months preceding the randomization
16. Patient on immunosuppressant
17. Patient with known hypersensitivity to gadoteric acid, meglumine or any drug containing gadolinium
Prospective Trial of Tranexamic Acid in Cardiac Surgery

Tranexamic acid, an antifibrinolytic drug, is wildly used in cardiac surgeries to decrease perioperative bleeding and allogenic transfusion. But the optimum dose of tranexamic acid is still unknown. We use three different doses to find which is the optimum dose of tranexamic acid in cardiopulmonary bypass cardiac surgery.


Eligibility Criteria:
Inclusion Criteria:

* Noncyanotic congenital heart disease patients requiring cardiac surgeries under cardiopulmonary bypass
* Rheumatic or recessive valvular disease patients requiring valvular repair or replacement under cardiopulmonary bypass
* Coronary artery disease patients requiring coronary artery bypass graft under cardiopulmonary bypass

Exclusion Criteria:

* Non-primary and emergency cardiac surgery
* Disorder in coagulation function before surgery
* Anemia before surgery
* Definite liver and renal dysfunction
* History of stroke
* Pregnancy and lactation
* Disabled in spirit or law
* Fatal conditions such as cancer
Pharmacokinetics of MCS in Healthy Volunteers

This study is to examine the pharmacokinetics, absorption and serum concentrations of MCS and other components after once-daily oral dosing of MCS.

This study is an open-label, multiple-dose study, whose objective is to examine the pharmacokinetics of MCS and other components after once-daily oral dosing for 21 days.

Subjects will undergo a 14-day washout phase and then enter the 21-day treatment phase. During the treatment phase, subjects will receive MCS, once-daily within one hour after the evening meal. After completion of the treatment phase, subjects will enter a post-treatment 42-day washout phase. Throughout each of these phases, blood samples will be collected and assayed for concentrations of MCS and other components. The duration of protocol participation is expected to be 77 days for each eligible subject who completes the study.

Eligibility Criteria:
Inclusion Criteria:

* Normal healthy volunteers
* 18 years of age or older

Exclusion Criteria:

* Subjects who can not comply with the study procedures or sign the informed consent form
Status Epilepticus in the Critically Ill Patients

Convulsive and Non Convulsive Status Epilepticus (SE) and Pseudo Status Epilepticus prospective registry.

Data collection using a standardized form : demographic data and data related to the SE, including circumstances of onset, dates and times of onset and of seizure control, on-scene clinical findings, clinical features of the seizures, pre-hospital and hospital care providers, timing of antiepileptic and supportive treatments, results of etiological investigations, cause of SE, type and dosage of antiepileptic drugs. Dates and times of EEG monitoring, EEG results. Outcomes including vital status and Glasgow Outcome Scale score at ICU and hospital discharge, day-90 and 1-year after SE and determined based on data in the ICU and/or neurologist charts and/or patients phone interview.


Eligibility Criteria:
Inclusion Criteria:

* SE defined as 5 min or more of (i) continuous clinical and/or electrographic seizure activity or (ii) recurrent seizure activity without recovery (returning to baseline) between seizures.
* age \>= 18 years

Exclusion Criteria:

* age \< 18 years
* postanoxic status epilepticus
Assessment of Quality of Life in Disorders of the Pelvic Floor

The purpose of this study is to compare the touch-screen version of the PFDI-20, PFIQ-7, PISQ 12 and SF-36 french questionnaires to their paper versions. The investigators hypothesize that the percentage of completely filled questionnaires will be higher in the touch-screen version.


Eligibility Criteria:
Inclusion Criteria:

* the patient has pelvic organ prolapse
* the patient requires a surgical intervention within the next 4 to 8 weeks
* the patient understands and reads french
* the patient is affiliated with a social security system
* the patient has given consent

Exclusion Criteria:

* the patient refuses to participate
* the patient is under guardianship
Ertapenem in Patients With Urosepsis

Ertapenem, a broad-spectrum carbapenem antibiotic, has shown promising in vitro activity agenst ESBL-producing Enterobacteriacae. This agent was licensed in United State of America and Europe for several clinical use in complicated intraabdominal infections, complicated skin and skin-structure infections, acute pelvic infections, complicated urinary tract infections and community-acquired pneumonia. In common with other beta-lactams, ertapenem exhibits primarily time-dependent activity, and the percentage of the exposure time during which the free drug concentration remain above the MIC (%T\>MIC) is the pharmacokinetic/pharmacodynamics (PK/PD) index that best correlates with efficacy. Pathophysiological changes in critically ill patients with severe infections resulting in altered PK patterns that may affect therapeutic plasma concentrations and achievement of PD have been found with several antimicrobial agents. The aim of the study was to determine the PK of ertapenem in patients with urosepsis.


Eligibility Criteria:
Inclusion Criteria:

* \>18 years of age
* Diagnosis of urosepsis

Exclusion Criteria:

* They were pregnant
* Circulatory shock (defined as a systolic blood pressure of \< 90 mmHg and pour tissue perfusion)
* Documented hypersensitivity to carbapenems
* Estimated creatinine clearance (CLcr) (determined by the Crockcroft-Goult method) of \< 30 mL/min
CaptHPV : Validation of the Method "CaptHPV" for the Diagnosis of Human Papillomavirus Associated Infiltrating Carcinomas

The current project is based on the assumption that a diagnosis of human papillomavirus associated Infiltrating Carcinomas can be made from a blood sample for patient with Cervical Cancer, Vulvar Cancer, Anal Cancer, Oropharynx Cancer, Oral Cavity Cancer or Penis Cancer at any stage of the disease and including surgical treatment for the small tumors.


Eligibility Criteria:
Inclusion Criteria:

* Age \>18 years
* Patient with cervical cancer, vulvar cancer, anal cancer, oropharynx cancer, oral cavity cancer or penis cancer
* Patient naive of any treatment for this pathology
* Patient capable and willing to follow all procedures of the study in accordance with the study
* Ability to provide an informed written consent form
* Affiliation to a social security system

Exclusion Criteria:

* Patients who have already undergone surgical treatment leading to complete removal of the lesions or who have started treatment with radiotherapy and / or chemotherapy
* Patient whose health status contraindicates a blood sample of 20 ml,
* Absence of informed written consent form
* Pregnant or breast feeding females
* Patients deprived of liberty or under supervision
Pathophysiological Mechanisms of Hepatopulmonary Influence in the Fontan Circulation

Randomisation between postoperative administration of an ACE-inhibitor or not.

Children that are undergoing elective surgery for the creation of a Fontan circulation will be randomised to postoperative administration of an ACE-inhibitor or not.

Determination of aldosteron, renine and ADH in serum preoperatively and 1h, 12h and 5 days postoperatively.

Eligibility Criteria:
Inclusion Criteria:

* All consecutive children with a univentricular heart disease undergoing elective surgery for creation of a Fontan circulation
* Parents have agreed with the study after informed consent

Exclusion Criteria:

* Urgent / Emergent surgery
* Preoperative use of an ACE-inhibitor
Comparison Between Transvaginal Mesh and Traditional Surgery for Pelvic Organ Prolapse

Pelvic organ prolapse is characterized by a lack of pelvic floor support causing the pelvic organs and vaginal walls to protrude. For decades, suture repair techniques have been the primary choice of surgical treatment when indicated.

Traditional surgical techniques are frequently associated with unsatisfying anatomical recurrence rates and it is plausible that inherently weak, or damaged, pelvic floor supportive tissues need to be reinforced by a permanent support to avoid the high rates of recurrences commonly described using traditional techniques. Over the years sporadic attempts have been made to introduce novel surgical techniques using a variety of biomaterials with varying success. Despite a lack of clinical safety data, or compelling clinical evidence demonstrating that it improves outcomes compared to traditional suture techniques, use of biomaterials in pelvic reconstructive surgery has become widespread in just a few years .

It is likely that biomaterials need to be "anchored" in tissues not afflicted by the disease, in order to provide the intended pelvic floor support. This has given rise to transvaginal surgical techniques using a transobturator approach passing the mesh through the arcus tendineous fascia pelvis, or the sacrospinous ligaments through a transgluteal approach. Short term data from concluded and on-going safety assessments of these techniques has provided promising results and satisfying clinical outcomes. The aim of the present study is to compare anterior mesh repair (PROLIFT®) with traditional suture repair in a randomised trial.


Eligibility Criteria:
Inclusion Criteria:

* Reproductive years in the past (biologically or reproductive decision)
* Prolapse of the anterior vaginal wall ≥POPQ-stadium II
* Prolapse specific pelvic symptom
* Being able to make an informed consent on participation
* Physically and cognitive capable of participating in the required follow-up
* No other pelvic floor surgery performed at the time of anterior repair
* No exclusion criteria fulfilled

Exclusion Criteria:

* Previous or current pelvic organ cancer (regardless of treatment)
* Severe rheumatic disease
* Insulin treated diabetes mellitus
* Connective tissue disorders (SLE, Sjögrens syndrome, Marfans syndrome, Ehlers Danhlos, collagenosis, polymyositis eller rheumatic myalgia)
* Current systemic steroid treatment
ACTIVATE in Public Housing

This multilevel, multidisciplinary, theoretically based, culturally sensitive, community-engaged intervention sets out to mitigate uptake barriers and non-adherence to vaccination schedules as recommended by the CDC and increase influenza, meningitis, pneumonia, VZV, and COVID-19 vaccine rates among under-resourced African American and Latino public housing residents in South Los Angeles.

Vaccinations are critical for preventing infectious diseases such as influenza, meningitis, pneumonia, varicella zoster virus (VZV), and COVID-19. Despite increasing national distribution and promotion of routine recommendations for adult vaccination, coverage remains low, with historically lower uptake among racial and ethnic minorities. This is compounded by higher levels of vaccine hesitancy, which may be attributed to a myriad of issues, including worsening social determinants, medical mistrust, and lack of access to health services. Specifically, African American and Latino public housing residents may benefit from public health campaigns and vaccination initiatives to support high vaccine uptake and confidence. This R01 proposal seeks to expand on a proven, multilevel, multidisciplinary, theoretically based, culturally sensitive, community-engaged intervention by expanding the Academic-Community Team for Improving Vaccine Acceptability and Targeted Engagement (ACTIVATE) program. Guided by a fusion of the Social-Ecological framework (SEM) and the Practical, Robust Implementation and Sustainability Model (PRISM), the ACTIVATE program is inclusive of health factors on the individual, interpersonal, community, and societal level and elements for successful implementation. Led by leadership triads of public housing resident leaders, nurse practitioner students, and public health students, the ACTIVATE program centers on mitigating uptake barriers and non-adherence to vaccination schedules as recommended by the CDC and to increase influenza, meningitis, pneumonia, VZV, and COVID-19 vaccine rates among under-resourced AA and Latino adults in South LA.

Eligibility Criteria:
Aim 3:

Inclusion Criteria:

* identify as Latinx or African American
* age 18 or older
* reside in one of the six collaborating public housing area
* Speak either English or Spanish
* Report vaccine hesitancy

Exclusion Criteria:

* Not a resident at one of the collaborating public housing areas
* Does not self-identify as African American or Latinx
* Age 17 and younger
* Unable to speak either English or Spanish
* Received all recommended vaccines for Influenza, Pneumonia, Meningitis, VZV, and COVID-19
* No reporting of vaccine hesitancy